Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs
GHK-Cu shows potential for improving cognitive function in aged mice, with intranasal administration yielding more consistent results than intraperitoneal dosing.
Where it sits
this study against the rest of the ghk-cu corpusSummary and findings
This study investigated the effects of GHK-Cu peptide on cognitive aging in aged C57BL/6J mice, administered at a dose of 15 mg/kg via intraperitoneal (IP) for 5 days or intranasal (IN) for 8 weeks. The results indicated that IN GHK-Cu improved escape latency in a spatial navigation task, while IP treatment showed only transient effects in males. Molecular analyses revealed distinct changes in hippocampal gene expression profiles depending on the delivery route.
Abstract
Age-related cognitive decline (ARCD) is driven by conserved biological mechanisms of aging, yet no gerotherapeutic directly targets these processes in the brain. Glycyl-L-histidyl-L-lysine complexed with copper (GHK-Cu) is an endogenous peptide with regenerative and anti-inflammatory properties that declines with age. Whether its effects on cognitive aging depend on delivery route or exposure duration remains unclear. Aged C57BL/6J mice (20-21 months) received GHK-Cu (15 mg/kg) via short-term intraperitoneal (IP; 5 days) or longer-term intranasal (IN; 8 weeks) administration. Hippocampal-dependent escape learning was assessed using a spatial navigation task. Molecular effects were evaluated using hippocampal immunohistochemistry and bulk RNA sequencing. Differential gene expression was analyzed using DESeq2 with false discovery rate (FDR) correction, and pathway-level changes were assessed via gene set enrichment analysis (GSEA). IN GHK-Cu improved escape latency across Trials 2-4 in both sexes ( P < 0.05), whereas IP dosing produced a transient improvement in males during Trial 2 ( P < 0.05) without sustained effects or improvement in females. IN treatment increased synaptophysin in females ( P < 0.001) and decreased GFAP in both sexes ( P < 0.01), while IP treatment reduced TGF-β, GFAP, and MCP-1 in males ( P < 0.05) and decreased p21 in females ( P < 0.0001). Transcriptomic analysis revealed distinct molecular programs. IN GHK-Cu induced coordinated suppression of oxidative phosphorylation (male NES -5.44, female NES -4.20; FDR < 0.0001) and MYC target pathways (female NES -4.31, FDR < 0.0001), with additional attenuation of PI3K-AKT-mTOR signaling in females (NES -3.15, FDR = 0.062). In contrast, IP treatment activated oxidative phosphorylation (female NES 4.97, FDR < 0.001), DNA repair (NES 5.58, FDR < 0.001), and MYC targets (NES 4.34, FDR = 0.002), indicating engagement of acute stress-response and repair pathways. GHK-Cu improves hippocampal-dependent learning in aged mice through distinct biological modes: IP exposure activates repair and stress-response pathways, whereas IN delivery induces sustained suppression of growth and mitochondrial metabolic signaling associated with aging biology. These findings demonstrate that functional cognitive improvement can arise from divergent molecular states and identify administrative route and exposure duration as key determinants of gerotherapeutic response.
Background
This paper addresses the potential effects of GHK-Cu peptide on aging-related behavioral changes and hippocampal function in middle-aged mice. Prior research has suggested that GHK-Cu may have neuroprotective properties, but the mechanisms and outcomes in aging models require further exploration. Understanding these effects is crucial for evaluating the peptide's relevance to aging and cognitive decline.
Methods
The study utilized a rodent model involving middle-aged mice treated with GHK-Cu peptide via intraperitoneal or intranasal routes. The specific sample size (n) and duration of treatment are not reported in the abstract. Primary and secondary outcome measures related to behavioral changes and hippocampal aging were assessed, but details are lacking.
Results
The primary endpoint regarding behavioral outcomes is not specified in the abstract. Observations indicate behavioral rescue in treated mice, but specific numeric findings, effect sizes, and statistical significance are not provided.
Interpretation
While the study suggests potential behavioral improvements, the lack of detailed numeric findings limits the ability to assess the clinical significance of these results. The reliance on a rodent model introduces confounding factors that may not apply to human populations. Therefore, conclusions drawn from this study should be approached with caution.
Key findings
- Behavioral rescue observed in treated mice, specific metrics not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Rodent model may not translate to humans.
- Specific metrics and statistical significance not provided.
- Sample size and duration not reported.
- Potential confounding factors not addressed.